跳至主要内容
临床试验/NCT00906685
NCT00906685已完成3 期

A Prospective, Randomized, Controlled Study on Intravitreal Bevacizumab (Avastin) for Central Retinal Vein Occlusion (CRVO)

Anders Kvanta1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
60
试验地点
1
主要终点
The proportion of patients gaining 15 ETDRS letters or more

研究概览

简要总结

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • CRVO with duration < 6 months
  • Visual acuity of 20/800 to 20/50

排除标准

  • CRVO with duration of > 6 months
  • previous treatment with anti-angiogenic drugs

研究组 & 干预措施

Intravitreal bevacizumab

Active Comparator

干预措施: bevacizumab (Drug)

Sham injection

Sham Comparator

干预措施: Sham bevacizumab injection (Drug)

结局指标

主要结局

The proportion of patients gaining 15 ETDRS letters or more

时间窗: 6 months

次要结局

  • Change in foveal thickness(6 months)
  • Cases of neovascular glaucoma(6 months)

研究者

发起方
Anders Kvanta
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Anders Kvanta

Professor

St. Erik Eye Hospital

研究点 (1)

Loading locations...

相似试验